NCT00546624View on ClinicalTrials.gov

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

PHASE2CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

February 28, 2003

Study Completion Date

February 28, 2003

Conditions

Anxiety Disorder

Interventions

DRUG

MK0777

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00546624 - GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026) | Biotech Hunter | Biotech Hunter